Vascular compliance in hypertension: Therapeutic implications

Current Diabetes Reports

Volumn 8, Issue 3, 2008, Pages 208-213

  Lee, Ho Won ^b   Karam, Jocelyn ^b   Hussain, Babar ^b   Winer, Nathaniel ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ALISKIREN; AMINOGUANIDINE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FISH OIL; GLYCERYL TRINITRATE; METFORMIN; METOPROLOL; NEBIVOLOL; NITRATE; ORAL ANTIDIABETIC AGENT; PENICILLAMINE; PERINDOPRIL; PIOGLITAZONE; RENIN INHIBITOR; SILDENAFIL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN;

AEROBIC EXERCISE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; BLOOD VESSEL COMPLIANCE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DIET RESTRICTION; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MONOTHERAPY; OBESITY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PULSE WAVE; REVIEW; SMOKING CESSATION; SYSTOLIC HYPERTENSION; WEIGHT REDUCTION; BLOOD VESSEL; COMPLIANCE (PHYSICAL);

BLOOD VESSELS; COMPLIANCE; HUMANS; HYPERTENSION;

EID: 52649119184     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0036-8     Document Type: Review

References (45)

1. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
2. Chobanian AV, Bakris GL, Black HR, et al.: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP, National Heart, Lung, and Blood Institute, National High BP Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High BP. Hypertension 2003, 42:1206-1252.
3. Wong ND, Lopez VA, L'Italien G, et al.: Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007, 167:2431-2436.
4. Bautista LE: Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens 2008 Jan 10 (Epub ahead of print).
5. Qureshi AI, Suri MF, Kirmani JF, et al.: Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005, 11:CR403-CR409.
6. Vasan RS, Larson MG, Leip EP, et al.: Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001, 358:1682-1686.
7. Larson MG, Leip EP, Evans JC, et al.: Impact of high-normal BP on the risk of cardiovascular disease. N Engl J Med 2001, 345:1337-1340.
8. Franklin SS, Mitchell GF: Aging, arterial function, and systolic hypertension. In Hypertension Primer. The Essentials of High Blood Pressure. Edited by Izzo JL Jr, Sica DA, Black HR. Philadelphia: Lippincott, Williams, and Wilkins; 2008:144-148.
9. Najjar SS, Scuteri A, Lakatta EG: Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 2005, 46:454-462.
10. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:303-304.
11. Laurent S, Boutouyrie P, Asmar R, et al.: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
12. Blacher J, Pannier B, Guerin AP, et al.: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998, 32:570-574.
13. Sutton-Tyrrell K, Najjar SS, Kupelian V, et al.: Aortic pulse wave velocity predicts mortality in a general population of well-functioning older adults. Circulation 2005, 111:3384-3390.
14. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
15. Vasan RS: Pathogenesis of elevated peripheral pulse pressure: some reflections and thinking forward. Hypertension 2008, 51:133-136.
16. O'Rourke MF, Nichols WW: Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005, 45:652-658.
17. Mitchell GF, Conlin PR, Dunlap ME, et al.: Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension 2008, 51:105-111.
18. Dart AM, Gatzka CD, Kingwell BA, et al.: Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension 2006, 47:785-790.
19. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S-209S.
20. Danias PG, Tritos NA, Stuber M, et al.: Comparison of aortic elasticity determined by cardiovascular magnetic resonance imaging in obese versus lean adults. Am J Cardiol 2003, 91:195-199.
21. Dengel DR, Kelly AS, Olson TP, et al.: Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 2006, 55:907-911.
22. Gates PE, Tanaka H, Hiatt WR, et al.: Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004, 44:35-41.
23. Seals DR, Tanaka H, Clevenger CM, et al.: Blood pressure reductions with exercise and sodium restriction in post-menopausal women with elevated systolic pressure: role of arterial stiffness. J Am Coll Cardiol 2001, 38:506-513.
24. Blendea MC, Bard M, Sowers JR, et al.: High-fat meal impairs vascular compliance in a subgroup of young healthy subjects. Metabolism 2005, 54:1337-1344.
25. Vaitkevicious PV, Fleg JL, Engel JH, et al.: Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993, 88:1456-1462.
26. Tanaka H, DeSouza CA, Seals DR: Absence of age-related increase in central arterial stiffness in physically active women. Arterioscler Thromb Vasc Biol 1998, 18:127-132.
27. Tanaka FA, Dinenno KD, Monahan CM, et al.: Aging, habitual exercise, and dynamic arterial compliance. Circulation 2000, 102:1270-1275.
28. Tanaka H, Safar ME: Influence of lifestyle modification on arterial stiffness and wave reflections. Am J Hypertens 2005, 18:137-144.
29. Miyachi M, Donato AJ, Yamamoto K, et al.: Greater age-related reductions in central arterial compliance in resistance-trained men. Hypertension 2003, 41:130-135.
30. Winer N, Sowers JR: Diabetes and arterial stiffening. Adv Cardiol 2007, 44:245-251.
31. Mahmud A, Feely J: Effect of smoking on arterial stiffness and pulse pressure amplification hypertension. Hypertension 2003, 41:183-187.
32. Benowitz NL: Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003, 46:91-111.
33. Siasos G, Tousoulis D, Vlachopoulos C, et al.: Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. Int J Cardiol 2007 Jun 22 (Epub ahead of print).
34. Winer N, Weber MA, Sowers JR: The effect of antihypertensive drugs on vascular compliance. Curr Hypertens Rep 2001, 3:297-304.
35. Rizzoni D, Porteri E, De Ciuceis, et al.: Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005, 45:659-665.
36. Savoia C, Touyz RM, Amiri F, et al.: Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.
37. Pool JL: Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007, 13(8 Suppl B):21-33.
38. Bank AJ, Kelly AS, Thelen AM, et al.: Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007, 20:777-783.
39. Zanchetti A: Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004, 1:17-32.
40. Chang JJ, Luchsinger JA, Shea S: Antihypertensive medication class and pulse-pressure in the elderly: analysis based on the Third National Health and Nutrition Examination Survey. Am J Med 2003, 115:536-542.
41. Morgan T, Lauri J, Bertram D, Anderson A: Effect of different anti-hypertensive drug classes on central aortic pressure. Am J Hypertens 2004, 17:118-123.
42. Fitchett DH, Simkus GJ, Beaudry JP, et al.: Reflected pressure waves in the ascending aorta: effect of glyceryl trinitrate. Cardiovasc Res 1988, 22:494-500.
43. Coughlan MT, Forbes JM, Cooper ME: Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007, 106:S54-S60.
44. Zieman SJ, Melenovsky V, Clattenburg L, et al.: Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007, 25:577-583.
45. Kass DA, Champion HC, Beavo JA: Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007, 101:1084-1095.